Is Early Menopause a Different Entity From Premature Ovarian Insufficiency?
Panagiotis AnagnostisIrene LambrinoudakiDimitrios G GoulisPublished in: Clinical endocrinology (2024)
Premature ovarian insufficiency (POI, defined as age at menopause < 40 years) affects 1%-3% of postmenopausal women. It is positively associated with an increased risk of diabetes mellitus, arterial hypertension, cardiovascular disease, osteoporosis, fractures, cognitive impairment, and depression. Early menopause (EM, defined as age at menopause < 45 years) is also associated with these adverse health consequences, in most cases to the same degree as in POI. Therefore, a unifying term for EM and POI, such as 'premature menopause', may be proposed, using the age threshold of < 45 years. This could provide broader coverage of these women, substantiating the need for prompt administration of menopausal hormone therapy (in this case, 'hormone replacement therapy'). However, the benefits of this approach, which precludes a higher oestrogen dose up to the normal age of menopause, need to be proven in well-designed randomized controlled trials.
Keyphrases
- postmenopausal women
- bone mineral density
- replacement therapy
- cardiovascular disease
- cognitive impairment
- randomized controlled trial
- arterial hypertension
- healthcare
- public health
- preterm infants
- type diabetes
- stem cells
- mental health
- polycystic ovary syndrome
- pregnant women
- clinical trial
- mesenchymal stem cells
- body composition
- pregnancy outcomes
- electronic health record
- breast cancer risk